L. J. Solin, R. Gray, F. L. Baehner, S. M. Butler, L. L. Hughes, C. Yoshizawa, D. B. Cherbavaz, S. Shak, D. L. Page, G. W. Sledge Jr., N. E. Davidson, J. N. Ingle, E. A. Perez, W. C. Wood, J. A. Sparano and S. Badve, “A Multigene Expression Assay to Predict Local Recurrence Risk for Ductal Carcinoma in Situ of the Breast,” Journal of the National Cancer Institute, Vol. 105, No. 10, 2013, pp. 701-710. http://dx.doi.org/10.1093/jnci/djt067

has been cited by the following article:

• TITLE: Current Treatment of DCIS

  AUTHORS: Christina Choy, Kefah Mokbel

  KEYWORDS: Early Breast Cancer; DCIS; Breast Cancer Diagnosis and Treatment

  JOURNAL NAME: Journal of Cancer Therapy, Vol.5 No.2, February 12, 2014

  ABSTRACT: Abstract: Ductal carcinoma in-situ DCIS is a heterogeneous entity in breast neoplasm with unpredictable biological behavior. This poses challenge in the management of DCIS. Various trials on DCIS have shown good outcome with integral treatment of adequate surgery, radiotherapy and hormonal therapy. Identification of subgroup of DCIS for radiotherapy and hormonal therapy could improve recurrence rate, contralateral tumours incidence and perhaps overall survival. Various risk score calculations could help to direct radiotherapy and hormonal treatment verses surgery alone and to avoid over treatment. Oncotype DX assay could be a new way of risk calculation to direct types of DCIS treatment. The recent increased use of MRI could increase the detection of DCIS and a more accurate extent of disease estimation. This article is a summary of major literatures and major trials result for DCIS.